Daichi Narushima

Department of Bioinformatics, National Cancer Center Research Institute

Disclosure: NO DISCLOSURE DATA

Presentation(s):

• ACTR-04 - BIOMARK: A phase II study of bevacizumab beyond progression for newly diagnosed glioblastoma: Safety, efficacy and prospective biomarker analysis

  Friday, November 22
  2:00 PM – 2:10 PM